Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis

Therapeutic Advances in Musculoskeletal Disease

Volumn 6, Issue 2, 2014, Pages 58-74

  Clain, Jeremy M ^a   Cartin Ceba, Rodrigo ^a   Fervenza, Fernando C ^a   Specks, Ulrich ^a  

^a MAYO CLINIC   (United States)

Author keywords

antineutrophil cytoplasmic antibody; antineutrophil cytoplasmic antibody associated vasculitis; eosinophilic granulomatosis with polyangiitis (Churg Strauss syndrome); granulomatosis with polyangiitis (Wegener s granulomatosis); microscopic polyangiitis; rituximab; vasculitis

Indexed keywords

ANTIHISTAMINIC AGENT; AZATHIOPRINE; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; LAMIVUDINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PARACETAMOL; PREDNISONE; RITUXIMAB;

B LYMPHOCYTE; BLADDER CANCER; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HEPATITIS B; HUMAN; IMMUNOGLOBULIN DEFICIENCY; KIDNEY TRANSPLANTATION; LEUKEMIA; LUNG TOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; VASCULITIS; VIRUS INFECTION;

EID: 84896290105     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X13516239     Document Type: Review

References (115)

1. Afif W. Loftus E. Jr Faubion W. Kane S. Bruining D. Hanson K. et al. (2010) Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 105: 1133–1139.
2. Albert D. Dunham J. Khan S. Stansberry J. Kolasinski S. Tsai D. et al. (2008) Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 67: 1724–1731.
3. Anolik J. Barnard J. Cappione A. Pugh-Bernard A. Felgar R. Looney R. et al. (2004) Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50: 3580–3590.
4. Aries P. Hellmich B. Voswinkel J. Both M. Nolle B. Holl-Ulrich K. et al. (2006) Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 65: 853–858.
5. Besada E. Bader L. Nossent H. (2013) Sustained hypogammaglobulinemia under rituximab maintenance therapy could increase the risk for serious infections: a report of two cases. Rheumatol Int 33: 1643–1644.
6. Besada E. Koldingsnes W. Nossent J. (2012) Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center. QJM 105: 545–550.
7. Bitzan M. Anselmo M. Carpineta L. (2009) Rituximab (B-cell depleting antibody) Associated Lung Injury (RALI): a pediatric case and systematic review of the literature. Pediatr Pulmonol 44: 922–934.
8. Boumpas D. Austin H. 3rd Vaughan E. Yarboro C. Klippel J. Balow J. (1993) Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119: 366–369.
9. Brihaye B. Aouba A. Pagnoux C. Cohen P. Lacassin F. Guillevin L. (2007) Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol 25: S23–S27.
10. Burton C. Kaczmarski R. Jan-Mohamed R. (2003) Interstitial pneumonitis related to rituximab therapy. N Engl J Med 348: 2690–2691; discussion 2690–2691.
11. Calabrese L. Molloy E. (2009) Therapy: rituximab and PML risk-informed decisions needed! Nat Rev Rheumatol 5: 528–529.
12. Carson K. Evens A. Richey E. Habermann T. Focosi D. Seymour J. et al. (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113: 4834–4840.
13. Cartin-Ceba R. Golbin J. Keogh K. Peikert T. Sanchez-Menendez M. Ytterberg S. et al. (2012) Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum 64: 3770–3778.
14. Cartin-Ceba R. Keogh K. Specks U. Sethi S. Fervenza F. (2011) Rituximab for the treatment of Churg–Strauss syndrome with renal involvement. Nephrol Dialysis Transplant 26: 2865–2871.
15. Chakravarty E. Murray E. Kelman A. Farmer P. (2011) Pregnancy outcomes after maternal exposure to rituximab. Blood 117: 1499–1506.
16. Choy D. Weiss A. Lin P. (1992) Progressive multifocal leukoencephalopathy following treatment for Wegener's granulomatosis. JAMA 268: 600–601.
17. Clifford D. Ances B. Costello C. Rosen-Schmidt S. Andersson M. Parks D. et al. (2011) Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 68: 1156–1164.
18. Clowse M. Copland S. Hsieh T. Chow S. Hoffman G. Merkel P. et al. (2011) Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). Arthritis Care Res 63: 1777–1781.
19. Cohen S. Emery P. Greenwald M. Dougados M. Furie R. Genovese M. et al. (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54: 2793–2806.
20. Cooper N. Arnold D. (2010) The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol 149: 3–13.
21. Cupps T. Edgar L. Fauci A. (1982) Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 128: 2453–2457.
22. Davis T. Grillo-Lopez A. White C. McLaughlin P. Czuczman M. Link B. et al. (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18: 3135–3143.
23. de Groot K. Harper L. Jayne D. Flores Suarez L. Gregorini G. Gross W. et al. (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150: 670–680.
24. de Groot K. Rasmussen N. Bacon P. Tervaert J. Feighery C. Gregorini G. et al. (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52: 2461–2469.
25. Demidem A. Lam T. Alas S. Hariharan K. Hanna N. Bonavida B. (1997) Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12: 177–186.
26. Donvik K. Omdal R. (2011) Churg–Strauss syndrome successfully treated with rituximab. Rheumatol Int 31: 89–91.
27. Edwards J. Szczepanski L. Szechinski J. Filipowicz-Sosnowska A. Emery P. Close D. et al. (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350: 2572–2581.
28. Eisenberg R. (2005) Update on rituximab. Ann Rheum Dis 64(Suppl. 4): iv55–iv57.
29. Eisenberg R. Looney R. (2005) The therapeutic potential of anti-CD20 “what do B-cells do?”. Clin Immunol 117: 207–213.
30. Eleftheriou D. Melo M. Marks S. Tullus K. Sills J. Cleary G. et al. (2009) Biologic therapy in primary systemic vasculitis of the young. Rheumatology 48: 978–986.
31. Emery P. Fleischmann R. Filipowicz-Sosnowska A. Schechtman J. Szczepanski L. Kavanaugh A. et al. (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54: 1390–1400.
32. Ennishi D. Terui Y. Yokoyama M. Mishima Y. Takahashi S. Takeuchi K. et al. (2008) Increased incidence of interstitial pneumonia by CHOP combined with rituximab. Int J Hematol 87: 393–397.
33. Eriksson P. (2005) Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 257: 540–548.
34. Fauci A. Haynes B. Katz P. Wolff S. (1983) Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98: 76–85.
35. Faurschou M. Sorensen I. Mellemkjaer L. Loft A. Thomsen B. Tvede N. et al. (2008) Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35: 100–105.
36. Fervenza F. Abraham R. Erickson S. Irazabal M. Eirin A. Specks U. et al. (2010) Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 5: 2188–2198.
37. Fervenza F. Cosio F. Erickson S. Specks U. Herzenberg A. Dillon J. et al. (2008) Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 73: 117–125.
38. Garcia Hernandez F. Ocana Medina C. Gonzalez Leon R. Garrido Rasco R. Colorado Bonilla R. Castillo Palma M. et al. (2007) [Rituximab for treatment of patients with systemic autoimmune diseases]. Med Clin 128: 458–462.
39. Geetha D. Eirin A. True K. Valentina Irazabal M. Specks U. Seo P. et al. (2011) Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: a multicenter experience. Transplantation 91: 1370–1375.
40. Geetha D. Seo P. Specks U. Fervenza F. (2007) Successful induction of remission with rituximab for relapse of ANCA-associated vasculitis post-kidney transplant: report of two cases. Am J Transplant 7: 2821–2825.
41. Gera M. Griffin M. Specks U. Leung N. Stegall M. Fervenza F. (2007) Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression. Kidney Int 71: 1296–1301.
42. Golay J. Zaffaroni L. Vaccari T. Lazzari M. Borleri G. Bernasconi S. et al. (2000) Biologic response of B lymphoma cells to Anti-CD20 monoclonal antibody rituximab in vitro: CD 55 and CD 59 regulate complement-mediated cell lysis. Blood 95: 3900–3908.
43. Goto S. Goto H. Tanoshima R. Kato H. Takahashi H. Sekiguchi O. et al. (2009) Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura. Int J Hematol 89: 305–309.
44. Gottenberg J. Guillevin L. Lambotte O. Combe B. Allanore Y. Cantagrel A. et al. (2005) Tolerance and short term Efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64: 913–920.
45. Greenwald M. Shergy W. Kaine J. Sweetser M. Gilder K. Linnik M. (2011) Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial. Arthritis Rheum 63: 622–632.
46. Guerry M. Brogan P. Bruce I. D'Cruz D. Harper L. Luqmani R. et al. (2012) Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology 51: 634–643.
47. Guillevin L. Pagnoux C. Karras A. Khoutra C. Aumaitre O. Cohen P. et al. (2012) Rituximab versus azathioprine for maintenance in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis. Arthritis Rheum 64: S706.
48. Gurcan H. Keskin D. Stern J. Nitzberg M. Shekhani H. Ahmed A. (2009) A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 9: 10–25.
49. Henes J. Fritz J. Koch S. Klein R. Horger M. Risler T. et al. (2007) Rituximab for treatment-resistant extensive Wegener's granulomatosis – additive effects of a maintenance treatment with leflunomide. Clin Rheumatol 26: 1711–1715.
50. Hermle T. Goestemeyer A. Sweny P. Burns A. (2007) Successful therapeutic use of rituximab in refractory Wegener's granulomatosis after renal transplantation. Clin Nephrol 68: 322–326.
51. Hoffman G. Kerr G. Leavitt R. Hallahan C. Lebovics R. Travis W. et al. (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116: 488–498.
52. Hoffman G. Specks U. (1998) Antineutrophil cytoplasmic antibodies. Arthritis Rheum 41: 1521–1537.
53. Hugle B. Solomon M. Harvey E. James A. Wadhwa A. Amin R. et al. (2010) Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener's granulomatosis. Arthritis Care Res 62: 1661–1664.
54. Huong D. Amoura Z. Duhaut P. Sbai A. Costedoat N. Wechsler B. et al. (2002) Risk of ovarian failure and fertility after intravenous cyclophosphamide. a study in 84 patients. J Rheumatol 29: 2571–2576.
55. Jayne D. Gaskin G. Rasmussen N. Abramowicz D. Ferrario F. Guillevin L. et al. (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18: 2180–2188.
56. Jayne D. Rasmussen N. Andrassy K. Bacon P. Tervaert J. Dadoniene J. et al. (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349: 36–44.
57. Jennette J. Falk R. Bacon P. Basu N. Cid M. Ferrario F. et al. (2013) 2012 Revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 65: 1–11.
58. Johnson P. Glennie M. (2003) The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 30: 3–8.
59. Jones J. Walsh M. Jayne D. (2011) Two-year follow-up results from a randomized trial of RTX versus CyP for ANCA-associated renal vasculitis: RITUXVAS. Clin Exp Immunol 164: 57.
60. Jones R. Ferraro A. Chaudhry A. Brogan P. Salama A. Smith K. et al. (2009) A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 60: 2156–2168.
61. Jones R. Tervaert J. Hauser T. Luqmani R. Morgan M. Peh C. et al. (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363: 211–220.
62. Kaushik V. Reddy H. Bucknall R. (2006) Successful use of rituximab in a patient with recalcitrant Churg–Strauss syndrome. Ann Rheum Dis 65: 1116–1117.
63. Keogh K. Wylam M. Stone J. Specks U. (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52: 262–268.
64. Keogh K. Ytterberg S. Fervenza F. Carlson K. Schroeder D. Specks U. (2006) Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Resp Crit Care Med 173: 180–187.
65. Koukoulaki M. Smith K. Jayne D. (2006) Rituximab in Churg–Strauss syndrome. Ann Rheum Dis 65: 557–559.
66. Larsen J. Jacobsen S. (2013) Rapid infusion with rituximab: short term safety in systemic autoimmune diseases. Rheumatol Int 33: 529–533.
67. Liu X. Hong X. Gu Y. Wang B. Luo Z. Cao J. (2008) Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma. Leuk Lymph 49: 1778–1783.
68. Looney R. Anolik J. Campbell D. Felgar R. Young F. Arend L. et al. (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis and rheumatism 50: 2580–2589.
69. Lovric S. Erdbruegger U. Kumpers P. Woywodt A. Koenecke C. Wedemeyer H. et al. (2009) Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients. Nephrol Dial Transplant 24: 179–185.
70. Mansfield N. Hamour S. Habib A. Tarzi R. Levy J. Griffith M. et al. (2011) Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. Nephrol Dial Transplant 26: 3280–3286.
71. Martin-Garrido I. Carmona E. Specks U. Limper A. (2013) Pneumocystis pneumonia in patients treated with rituximab. Chest 144: 258-265.
72. Martinez Del Pero M. Chaudhry A. Jones R. Sivasothy P. Jani P. Jayne D. (2009) B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Clin Otolaryngol 34: 328–335.
73. Molloy E. Calabrese L. (2012) Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 64: 3043–3051.
74. Morgan M. Drayson M. Savage C. Harper L. (2011) Addition of infliximab to standard therapy for ANCA-associated vasculitis. Nephron Clin Pract 117: c89–c97.
75. Nachman P. Hogan S. Jennette J. Falk R. (1996) Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 7: 33–39.
76. Omdal R. Wildhagen K. Hansen T. Gunnarsson R. Kristoffersen G. (2005) Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol 34: 229–232.
77. Ostensen M. Forger F. (2011) Treatment with biologics of pregnant patients with rheumatic diseases. Curr Opin Rheumatol 23: 293–298.
78. Pendergraft W. McGrath M. Murphy A. Murphy P. Laliberte K. Niles J. (2013) Gestational rituximab exposure in women with vasculitis. La Presse Médicale 42: 776–777.
79. Pepper R. Fabre M. Pavesio C. Gaskin G. Jones R. Jayne D. et al. (2008) Rituximab is effective in the treatment of refractory Churg–Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology 47: 1104–1105.
80. Perceau G. Diris N. Estines O. Derancourt C. Levy S. Bernard P. (2006) Late lethal hepatitis b virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 155: 1053–1056.
81. Popa E. Stegeman C. Bos N. Kallenberg C. Tervaert J. (1999) Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 103: 885–894.
82. Ramos-Casals M. Garcia-Hernandez F. de Ramon E. Callejas J. Martinez-Berriotxoa A. Pallares L. et al. (2010) Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 28: 468–476.
83. Rhee E. Laliberte K. Niles J. (2010) Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 5: 1394–1400.
84. Roccatello D. Baldovino S. Alpa M. Rossi D. Napoli F. Naretto C. et al. (2008) Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 26: S67–S71.
85. Roccatello D. Sciascia S. Rossi D. Alpa M. Naretto C. Russo A. et al. (2011) Long-term effects of rituximab added to cyclophosphamide in refractory patients with vasculitis. Am J Nephrol 34: 175–180.
86. Roubaud-Baudron C. Pagnoux C. Meaux-Ruault N. Grasland A. Zoulim A. Le Guern V. et al. (2012) Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 39: 125–130.
87. Saech J. Owczarczyk K. Rosgen S. Petereit H. Hallek M. Rubbert-Roth A. (2010) Successful use of rituximab in a patient with Churg–Strauss syndrome and refractory central nervous system involvement. Ann Rheum Dis 69: 1254–1255.
88. Sanchez-Cano D. Callejas-Rubio J. Ortego-Centeno N. (2008) Effect of rituximab on refractory Wegener granulomatosis with predominant granulomatous disease. J Clin Rheumatol 14: 92–93.
89. Sarrecchia C. Cappelli A. Aiello P. (2005) HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 11: 189–191.
90. Seo P. Specks U. Keogh K. (2008) Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J Rheumatol 35: 2017–2023.
91. Shan D. Ledbetter J. Press O. (2000) Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 48: 673–683.
92. Smith K. Jones R. Burns S. Jayne D. (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 54: 2970–2982.
93. Smith R. Jones R. Guerry M. Laurino S. Catapano F. Chaudhry A. et al. (2012) Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64: 3760–3769.
94. Sneller M. Hoffman G. Talar-Williams C. Kerr G. Hallahan C. Fauci A. (1995) An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 38: 608–613.
95. Specks U. Fervenza F. McDonald T. Hogan M. (2001) Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 44: 2836–2840.
96. Specks U. Merkel P. Seo P. Spiera R. Langford C. Hoffman G. (2011) Immunoglobulin concentrations and infection risk among patients with ANCA-associated vasculitis treated with rituximab or cyclophosphamide. Arthritis Rheum 63: 789.
97. Specks U. Merkel P. Seo P. Spiera R. Langford C. Hoffman G. et al. (2013) Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 369: 417–427.
98. Stasi R. Stipa E. Del Poeta G. Amadori S. Newland A. Provan D. (2006) Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology 45: 1432–1436.
99. Stevenson H. Fauci A. (1980) Activation of human B lymphocytes. XII. Differential effects of in vitro cyclophosphamide on human lymphocyte subpopulations involved in B-cell activation. Immunology 39: 391–397.
100. Stone J. Hoffman G. Merkel P. Min Y. Uhlfelder M. Hellmann D. et al. (2001) A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 44: 912–920.
101. Stone J. Merkel P. Seo P. Spiera R. Langford C. Hoffman G. et al. (2011) Extended follow-up of treatment with rituximab versus cyclophosphamide for remission-induction of ANCA-associated vasculitis: which subsets are at greatest risk for flare? Arthritis Rheum 63: S946–S947.
102. Stone J. Merkel P. Spiera R. Seo P. Langford C. Hoffman G. et al. (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363: 221–232.
103. Szpirt W. Heaf J. Petersen J. (2011) Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis – a clinical randomized controlled trial. Nephrol Dial Transplant 26: 206–213.
104. Talar-Williams C. Hijazi Y. Walther M. Linehan W. Hallahan C. Lubensky I. et al. (1996) Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124: 477–484.
105. Taylor S. Salama A. Joshi L. Pusey C. Lightman S. (2009) Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 60: 1540–1547.
106. Tedder T. Engel P. (1994) CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 15: 450–454.
107. Tesfa D. Ajeganova S. Hagglund H. Sander B. Fadeel B. Hafstrom I. et al. (2011) Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 63: 2209–2214.
108. Uchida J. Hamaguchi Y. Oliver J. Ravetch J. Poe J. Haas K. et al. (2004) The innate mononuclear phagocyte network depletes B lymphocytes through FC receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199: 1659–1669.
109. Venhoff N. Effelsberg N. Salzer U. Warnatz K. Peter H. Lebrecht D. et al. (2012) Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PloS ONE 7: e37626.
110. Walsh M. Catapano F. Szpirt W. Thorlund K. Bruchfeld A. Guillevin L. et al. (2011) Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. AmJ Kidney Dis 57: 566–574.
111. Walsh M. Chaudhry A. Jayne D. (2008) Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis 67: 1322–1327.
112. Walsh M. Merkel P. Peh C. Szpirt W. Guillevin L. Pusey C. et al. (2013) plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 14: 73.
113. Walton E. (1958) Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 2: 265–270.
114. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group (2005) Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352: 351-361.
115. Yannick P. (2013) Drug-induced Pneumonitis in Patients Treated with Rituximab in a Tertiary Care Hospital in Canada, C38. Pulmonary and Systemic Inflammation. New York: American Thoracic Society.